FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said the U.S. Food and Drug Administration has granted Fast Track designation to QTORIN™ rapamycin for the treatment of angiokeratomas, a rare …
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path Read More